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ABSTRACT
INTRODUCTION: Lycium barbarum L., known as Goji berry, is widely used as a medicinal and func-
tional food. Apart from the positive therapeutic properties it possesses, it can inhibit enzymes involved in 
the metabolism of drugs and it can cause herb-drug interactions (HDIs).
AIM: The aim of the study is evaluation of the potential of polysaccharide and polyphenolic fractions iso-
lated from L. barbarum fruits to inhibit the activity of CYP3A4 and CYP2C9.
MATERIALS AND METHODS: The inhibitory effects of polysaccharide and polyphenolic fractions iso-
lated from L. barbarum on CYP3A4 and CYP2C9 activity were determined using Vivid® CYP3A4 and CY-
P2C9 Green Screening Kits.
RESULTS: Both fractions inhibit the activity of investigated CYP isoenzymes. The polyphenolic fraction 
was more potent with IC50 values of 0.119 mg/mL and 0.048 mg/mL against CYP3A4 and CYP2C9, respec-
tively. The polysaccharide fraction has inhibited CYP3A4 and CYP2C9 with IC50 values of 2.244 mg/mL and 
4.094 mg/mL, respectively.
CONCLUSION: The use of beverages based on L.barbarum can lead to herb-drug interactions (HDIs). 
Further research in this direction will assess the significance of these interactions.
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INTRODUCTION
Lycium barbarum L. (Solanaceae), known as 
Goji berry, has been used in southeastern Asian 
countries for many years, as a medicinal and func-
tional food. Nowadays, it is gaining popularity in 
Western countries because of the powerful antioxi-
dant properties it possesses, contributing to anti-ag-
ing, antitumor activity and many other described 
positive properties (1-4). The main part of this plant 
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that is used is the fruit. L. barbarum polysaccharides 
(LBPs) are the most studied components in the fruits 
and are referred to as the primary for inducing phar-
macological effects (5-7). Other components, such 
as flavonoids, phenolic acids, anthocyanins, carot-
enoids, etc., also contribute to the pharmacological 
effects of L.barbarum fruits. 
Cytochrome P450 (CYP) plays an important 
role in the biotransformation of xenobiotics, includ-
ing the most used therapeutic drugs. The CYP3A4 
and CYP2C9 isoenzymes take part in the metabo-
lism of nearly 50-60% of the marketed drugs, mak-
ing them susceptible to develop of pharmacokinet-
ic drug interactions (8). Herbal medicines are now-
adays widely used by patients claiming to be effec-
tive agents with little or negligible undesirable ef-
fects. Many of them, however, are likely to affect 
cytochrome enzymes, inhibit or induce them, and 
could lead to important clinical herb-drug interac-
tions (HDIs) (9-11). It is therefore necessary to study 
these plant products in detail to assess their potential 
for interactions.
AIM
The aim of the present study is to evaluate the 
potential of polysaccharide and polyphenolic frac-
tions isolated from L. barbarum fruits to inhibit the 
activity of CYP3A4 and CYP2C9. 
MATERIALS AND METHODS
Plant Material and Fractions
L. barbarum fruits (Lot №: L05042017) were 
provided by Paula Fruits Ltd – an official import-
er of Goji berries for Bulgaria with guaranteed Chi-
nese origin. The preparation of the polysaccharide 
and polyphenolic extracts used in the study and their 
analysis is described in detail in our previous arti-
cle (12). All chemicals used for extraction and analy-
sis were of analytical grade and were purchased from 
the local representatives of Merck (Darmstadt, Ger-
many) and Sigma (St. Louis, USA), unless otherwise 
indicated.
Determination of CYP3A4 and CYP2C9 Ac-
tivity with Vivid® P450 Assay Kits 
The inhibitory effects of polysaccharide and 
polyphenolic fractions isolated from Lycium bar-
barum on CYP3A4 and CYP2C9 activity were de-
termined using Vivid® CYP3A4 Green Screening 
Kit and Vivid® CYP2C9 Green Screening Kit fol-
lowing manufacturer’s instruction (13). Stock so-
lutions (2.0 mg/mL) were prepared from both used 
fractions and the following concentrations were ob-
tained by dilution: 2.0 mg/mL, 1.0 mg/mL, 0.5 mg/
mL, 0.25 mg/mL, 0.125 mg/mL and 0.0625 mg/mL. 
The samples in each well were mixed with a master 
pre-mix, comprising reaction buffer, CYP450 BAC-
ULOSOMES® (CYP3A4 or CYP2C9) reagent and re-
generation system, which contained glucose-6-phos-
phate and glucose-6-phosphate dehydrogenase. The 
mixture was incubated at room temperature for 20 
min. We performed a pre-read of the fluorescence 
at this point to determine if there were fluorescent 
compounds in the polysaccharide and polypheno-
lic fractions and no fluorescence was detected. Fol-
lowing incubation, CYP enzyme-specific substrate 
di(benzyloxymethoxy)fluorescein (DBOMF, Viv-
id green substrate for CYP3A4) or benzyloxy-meth-
yl-fluorescein (BOMF, Vivid green substrate for CY-
P2C9) and NADP+ were added and the mixture was 
incubated at room temperature for 30 min. The re-
action was stopped by the addition of 10 mcM keto-
conazole (CYP3A4) or 30 mcM Sulfaphenazole (CY-
P2C9) and enzyme activity was evaluated by mea-
suring the fluorescence at excitation/emission wave-
length of 485/528 nm (BioTek Synergy 2). To deter-
mine reaction kinetics, we performed the Kinetic 
Measurement Protocol (described in the manufac-
turer’s instruction (13)), where the fluorescence was 
measured at 5 min intervals for 30 min.
Statistical Analysis
To calculate the percentage of inhibition, we 
used the following equation: Percentage of inhibition 
= 100 − ([Signal of well (RFU, relative fluorescence 
units) − Blank]/[Solvent control − Blank] ×100). To 
build the graphs and to calculate IC50 with a 95% 
confidence interval, we used four-parameter logistic 
curve (4PL) generated by the GraphPad Prism ver-
sion 6.0 (GraphPad Software, USA). For extrapola-
tion of the results in logarithmic manner, we used 
Microsoft Excel 2010. 
RESULTS
Both isolated fractions from L. barbarum were 
tested for inhibition on CYP3A4 and CYP2C9.
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Assessment of CYP3A4 Inhibition by L. bar-
barum Fractions
To assess the inhibition of CYP3A4, we applied 
the polysaccharide and polyphenolic fractions from 
L. barbarum in following concentrations – 2.0 mg/
mL, 1.0 mg/mL, 0.5 mg/mL, 0.25 mg/mL, 0.125 mg/
mL and 0.0625 mg/mL. Results are shown in Fig. 1.
The polysaccharide fraction did not show a 
strong inhibitory effect on the CYP3A4 isoenzyme. 
In the highest used concentration (2.0 mg/mL) 40% 
of the activity of the isoenzyme was inhibited. The 
polyphenolic fraction has showed a potent inhibition 
on CYP3A4. The highest concentration (2.0 mg/mL) 
inhibits 90% of the activity of the isoenzyme.
Assessment of CYP2C9 Inhibition by L. bar-
barum Fractions
The fractions isolated from L.barbarum were 
also tested for inhibition of CYP2C9 in the same 
concentration manner. The results on CYP2C9 were 
similar to those on CYP3A4 (Fig. 2).
The polysaccharide fraction has shown negli-
gible inhibition on CYP2C9, while the polyphenolic 
fraction exhibits a significant inhibition of the isoen-
zyme activity.
Determination of IC50 Values
In order to determine the approximate IC50 val-
ues with 95% confidence interval (CI) of the indi-
vidual fractions on the CYP3A4 and CYP2C9 isoen-
zymes, we have extrapolated the results in logarith-
mic manner. The results are summarized in Table 1.
As can be seen from the table, the polyphenol 
fraction is significantly more potent than the poly-
saccharide in terms of the inhibition of CYP3A4 and 
CYP2C9, ~ 20 folds and 85 folds, respectively. 
DISCUSSION
A “superfruit” or “superfood”, as Lycium bar-
barum L. (Goji berry) is known in the Western coun-
tries, has many useful nutritional and medicinal 
properties such as antioxidant, antidiabetic, antihy-
perlipidemic, immunomodulatory, anticancer, neu-
roprotective etc. (14, 15). Despite all the beneficial ef-
fects of consumption of L. barbarum fruits, there are 
many reports that announce for serious drug inter-
actions with enzymes involved in the first phase of 
drug metabolism. 
Our results indicate that L. barbarum extracts 
have inhibitory effects on investigated CYPs – CY-
P3A4 and CYP2C9. Furthermore, the polyphenolic 
fraction has more a pronounced effect than the poly-
saccharide fraction (Table 1). This would presum-
ably lead to possible herb-drug interactions (HDIs). 
These results are confirmed by other authors. Liu R 
Fig. 1. Inhibition of CYP3A4 isoenzyme by polysaccharide 
and polyphenolic fractions isolated from L. barbarum 
fruits
Fig. 2. Inhibition of CYP2C9 isoenzyme by polysaccharide 
and polyphenolic fractions isolated from L. barbarum 
fruits
IC50 values (95% CI) on CYP3A4 IC50 values (95% CI) on CYP2C9
Polysaccharide fraction 2.244 mg/ml (1.593 to 3.161) 4.094 mg/ml (2.723 to 6.158)
Polyphenolic fraction 0.119 mg/ml (0.086 to 0.166) 0.048 mg/ml (0.036 to 0.063)
Table 1. IC50 values with 95% confidence interval of the fractions isolated from L. barbarum on the activity of the CY-
P3A4 and CYP2C9 isoenzymes
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et al. (16) investigated in vitro juice, water and eth-
anol extracts of L. barbarum against major human 
phase I metabolism enzymes and proves significant 
inhibition. They also find that mechanism of inhibi-
tion is rather competitive than mechanism-based. In 
our study, the conducted kinetic model demonstrat-
ed shifting the curves to the right, which suggests ex-
cluding mechanism-based inhibition. We observed 
a concentration-dependent inhibition of isozymes, 
suggesting that the mechanism is competitive.
There are several published studies that dem-
onstrate the significance of possible interactions of 
L. barbarum in clinical conditions (17-19). All three 
cited studies described interactions between L. bar-
barum and warfarin. Warfarin is from the group 
of anticoagulants, with a narrow therapeutic index 
and its more active enantiomer, S-warfarin, is me-
tabolized by CYP2C9 (20). In all three cases, patients 
have consumed drinks based on L. barbarum – wine, 
juice or herbal tea, concomitant with warfarin and 
increased INR values were recorded. They have con-
cluded that the interaction is associated with inhibi-
tion of warfarin metabolism and have recommend-
ed caution when consuming beverages containing L. 
barbarum simultaneously with warfarin.
CONCLUSION
In this study we demonstrated the potential of 
L. barbarum to inhibit two isoenzymes – CYP3A4 
and CYP2C9, which play major role in the biotrans-
formation of the drugs. We have also shown that 
polyphenolic components are more potent inhibitors 
of the isoenzymes than polysaccharide. The usage of 
beverages based on L. barbarum can lead to HDIs. 
Further research in this direction will assess the sig-
nificance of these interactions.
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